Sign inJoin waitlistJoin the waitlist

Lisa Bodei

Director of Targeted Radionuclide Therapy · New York Presbyterian Hospital

Credentials: · · · ·

History

Memorial Sloan Kettering Bergen
2025–Present

European Institute of Oncology
1998–1999
University of Pisa
1995–1998
UNIV DI PISA, PISA
1991–1995

Research

Radiopharmaceutical therapy in cancer: clinical advances and challenges
Review · Nature Reviews Drug Discovery · 2020 · 680 citations
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
European Journal of Nuclear Medicine and Molecular Imaging · 2013 · First of 12 authors · Corresponding · 576 citations
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term…
The Lancet Oncology · 2021 · 510 citations

IM
Irvin Modlin
49 papers
Heiko Schöder
19 papers
Diane Reidy-Lagunes
16 papers
Thomas Hope
13 papers
JS
Jonathan Strosberg
12 papers
MM
Michael Morris
11 papers
WW
Wolfgang Weber
10 papers
NR
Nitya Raj
9 papers
Vikas Prasad
9 papers
EM
Erik Mittra
8 papers
Simone Krebs
8 papers
Charles Rudin
7 papers

Grants

Characterizing the Theranostic Potential of DLL3-Targeting Agents in High-Grade Neuroendocrine Carcinomas of the Lung and Prostate
National Cancer Institute · R01
Contact PI · $1.4M · Sloan-Kettering Inst Can Research
2024–2029

Clinical trials

A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate
Principal investigator · Not yet recruiting · Phase 1
Memorial Sloan Kettering Cancer Center
2026–2030
Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors
Principal investigator · Active not recruiting
Memorial Sloan Kettering Cancer Center
2024–2027
177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
Principal investigator · Unknown · Phase 1
Molecular Targeting Technologies, Inc.
2022–2025
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
Principal investigator · Active not recruiting · Early phase 1
Memorial Sloan Kettering Cancer Center
2020–2027